Tata India Pharma & Healthcare Growth Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹5,000

Tata India Pharma & Healthcare Growth Direct Plan

NAV
₹35.7413
+0.54%
(23 Jul)
AUM
1,282 Cr
TER
0.62%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+12.9%
+5.2%
-2.1%
-3.3%
-5.6%
3Y
+25.7%
+34.1%
+37.2%
+37.5%
+34.9%
5Y
+23.3%
+37.9%
+31.3%
+29.7%
+32.4%
ALL
+14.2%
+17.7%
+12.2%
+17.3%
+26.1%
VOL
15.6%
18.1%
20.3%
19.8%
22.5%
TER
0.6%
1.1%
0.8%
0.9%
0.5%
AUM
₹1,282 Cr
₹8,043 Cr
₹5,427 Cr
₹1,439 Cr
₹5,687 Cr
INFO
0.91
0.98
0.60
0.87
1.16
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Tata India Pharma & Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 30th Jun
Top holdings
Sun Pharmaceuticals Industries Ltd
11.2%
Cash / Net Current Asset
7.4%
Apollo Hospitals Enterprise Ltd
7.2%
Cipla Ltd
5.8%
Divi's Laboratories Ltd
5.6%
Aurobindo Pharma Ltd
5.4%
Fortis Healthcare Ltd
5.3%
Lupin Ltd
4.6%
Aster DM Healthcare Ltd Ordinary Shares
4.4%
Wockhardt Ltd
3.7%
Top industry exposure
Healthcare
89.0%
Basic Materials
2.3%
Financial Services
1.0%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹5,000
Additional lumpsum
₹1,000
Portfolio turnover
17%
Lock-in period
-
Exit load
• 0.25% for redemption within 30 days
Fund objective
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Fund manager(s)
Rajat Srivastava

FAQs